RIPK2 and Alzheimer disease: Overall, these findings suggest that the therapeutic effect of Avn-C in mitigating HFD-aggravated AD-related pathologies is driven by its anti-neuroinflammatory properties and may involve the NOD1/RIP2/NF-κB signaling pathway.